# Tasly Capital

> Tasly Capital is a VC fund in Tianjin backing Medical, Biotechnology and Medical Device. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Tianjin, China
- Total investments: 15
- Last investment: Mar 2026
- Lead investor: 47%
- Last updated: Aug 2026

Tasly Capital is an investment arm of Tasly, a Chinese pharmaceutical company.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $14M–$28M |
| Series B | $15M–$42M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 9 | 60% |
| Biotechnology | 7 | 47% |
| Medical Device | 7 | 47% |
| Health Care | 6 | 40% |
| Therapeutics | 2 | 13% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 40% |
| Series B | 5 | 33% |
| Seed | 2 | 13% |
| Series C | 2 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bite Micro | Better Micro Medical is a medical device company that is characterized by intervention and non-implantation, and offers doctors with comprehensive solutions in the field of peripheral vascular and structural heart disease. | $14.5M | Series B | Mar 16, 2026 |  |
| Regend Therapeutics | Regend Therapeutics focuses on the human organ regenerative medicine business and is a global leader in this field. Its core product REGEND001 cell preparation has been accepted by the State Food and Drug Administration and is the world's first autologous stem cell product for respiratory diseases. The company is also the first company inChina to be registered by the National Health and Health Commission and the Food and Drug Administration, and is allowed to conduct clinical research on stem cells (Registration No.: CMR-20161214-1002). It is also the first batch of key research and development programs of the Ministry of Science and Technology. And companies that transform research topics. At present, the company has passed ISO9001:2008 quality management system certification, and the stem cell preparation has passed the China Metrology Accreditation (CMA), China Conformity Assessment Committee (CNAS) and IAF International Mutual Recognition. All clinical programs of Jimmy Suisheng are strictly in accordance with the regulations of the National Health Care Commission and the Food and Drug Administration, and are registered with the National Trial Global Database of the National Institutes of Health. | $50.6M | Series C | Feb 11, 2026 |  |
| Libo Biotech | Libo Biotech is a cutting-edge biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics that specifically target RNA. | $13.9M | Seed | Aug 11, 2025 |  |
| Singular Medical | Singular Medical is a technology company specializing in R&D and industrialization of cardiac rhythm management (CRM) products. The company builds a complete technical platform and is a supplier of full line of CRM products, which provides a complete range of solutions, from detection to follow-up for large amounts of cardiac patients. | $20.7M | Series C | Mar 12, 2025 |  |
| PulseCare | PulseCare is a medtech company that specializes in innovative medical devices and solutions for cardiac and pan-vascular treatment. | $14M | Series A | Aug 21, 2024 |  |
| LeadBio Tech | LeadBio Tech is a biotechnology company that specializes in the development of bioartificial blood vessel medical devices. |  | Series A | Jun 14, 2024 |  |
| UniXell Biotechnology | Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs. | $13.8M | Series A | Apr 02, 2024 |  |
| EurekaBio | EurekaBio offers solutions for cancer immunotherapy including automatic cell therapy manufacturing equipment and a vector production platform | $41.7M | Series B | Feb 21, 2024 |  |
| Deco Medical | Deco Medical is a myocardial repair service provider and an innovative medical device research and development enterprise. |  | Seed | Feb 14, 2024 |  |
| Tingsheng Technology | TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digitalheart model. | $14.7M | Series B | Jan 29, 2023 |  |

10 of 15 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 2 deals together
- [ABC Capital](https://shizune.co/investors/profile/abccapital) — VC Fund, 1 deal together
- [Angel Plus China](https://shizune.co/investors/profile/angel-plus-china) — VC Fund, 1 deal together
- [Ascendum Capital](https://shizune.co/investors/profile/ascendum-capital) — VC Fund, 1 deal together
- [Beta Fund](https://shizune.co/investors/profile/beta-fund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Medical Device VC Funds in China](https://shizune.co/investors/medical-device-vc-funds-china)

## FAQ

### What does Tasly Capital invest in?

Tasly Capital invests primarily in Medical, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Tasly Capital's check size?

Tasly Capital typically joins rounds of $14M–$28M at Series A and $15M–$42M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tasly Capital participates in.

### When did Tasly Capital last invest?

The most recent investment recorded for Tasly Capital closed in Mar 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co